Abstracts tagged "Pediatric rheumatology"

Abstract Number: 0414 • ACR Convergence 2024
Relationship Between Culture Negative Infectious Osteomyelitis and Chronic Nonbacterial Osteomyelitis
Andrew Grim¹, Yongdong (Dan) Zhao², Christine Wang¹, Erin Janssen³, Jessica Turnier⁴, Anastasia Hyrhorczuk¹ and Nadine Saad¹, ¹University of Michigan, Ann Arbor, MI, ²University of Washington, Redmond, WA, ³CS Mott Children's Hospital, Ann Arbor, MI, ⁴University of Michigan, Saline, MI
Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is a rare autoinflammatory bone disorder. Some patients with CNO may present acutely and be misdiagnosed as infectious osteomyelitis (IO).…
Abstract Number: 1259 • ACR Convergence 2024
Adverse Childhood Experiences Are Associated with Patient-Reported Outcomes in Adolescents and Young Adults with Systemic Lupus
Tamar Rubinstein¹, Avni Dave², Terrence Calistro³, Kimberly Rapoza³, Shari Salzhauer Berkowitz³, Joyce Hui-Yuen⁴, Zanab Mian⁵, Emily Masi⁶ and Kathleen Kenney-Riley⁷, ¹Albert Einstein College of Medicine, White Plains, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Mercy University, Dobbs Ferry, NY, ⁴Northwell Health, Cohen Children's Medical Center, Great Neck, NY, ⁵Cohen Children's Medical Center, Lake Success, NY, ⁶Cohen Children's Medical Center, Floral Park, NY, ⁷Albert Einstein College of Medicine, Port Chester, NY
Background/Purpose: Adverse childhood experiences (ACEs), are major life stressors that occur before the age of 18 and include experiences of household dysfunction. Recently, prior trauma,…
Abstract Number: 1276 • ACR Convergence 2024
Therapeutic Drug Monitoring (TDM) of Rituximab to Predict Early B-Cell Repopulation in Children
Rana Alsulami¹, Bindiya Chugani², Joley Johnstone², Ann Yeh², Floris Loeff³, Linda Hiraki², Andrea Knight⁴, Deborah Levy² and Ruud Verstegen², ¹University of Toronto, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Sanquin Diagnostic Services, Amsterdam, Netherlands, ⁴Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Rituximab is increasingly used in pediatric inflammatory diseases, with dosing extrapolated from adult data due to a lack of pediatric-specific pharmacokinetic (PK) information. Children…
Abstract Number: 1742 • ACR Convergence 2024
Multi-Center Use of an Online Case-Based Simulation to Educate Pediatric Trainees on Musculoskeletal Complaints and High-Value Care
Marina Latif¹, Kyla Driest², Erin Frank³, Allayne Stephans³, Stacey Tarvin⁴ and Angela Robinson⁵, ¹Case Western Reserve University School of Medicine, Cleveland, OH, ²Nationwide Children's Hospital, Columbus, OH, ³Rainbow Babies and Children's Hospital, Cleveland, OH, ⁴Indiana University School of Medicine, Indianapolis, IN, ⁵Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Excessive healthcare spending in the United States remains a growing concern, and teaching high-value care is essential to combat wasted costs. It is…
Abstract Number: 1794 • ACR Convergence 2024
Biobehavioral Basis and Outcomes of Cognitive Dysfunction in Childhood Systemic Lupus Erythematosus
Hanne van der Heijden¹, Andrea Knight², Itamar Ronen³, Gabrielle Alonzi⁴, Kyle McBrearty⁴, Aditi Deokar⁴, Joseph Gonzalez-Heydrich⁴, Joyce Chang⁴ and Jaymin Upadhyay⁵, ¹Boston Children's Hospital Harvard Medical School, Boston, MA, ²Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ³Brighton and Sussex Medical School, University of Sussex, Brighton, UK, Brighton, United Kingdom, ⁴Boston Children's Hospital, Boston, MA, ⁵Boston Children's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Cognitive dysfunction (CD) in childhood-onset SLE (cSLE) is undertreated yet profoundly impacts lifelong health-related quality of life. Investigating CD in cSLE is crucial, given…
Abstract Number: 2179 • ACR Convergence 2024
Evaluation of Diagnostic Concordance Between Telehealth Encounters and In-Person Follow-up Assessments in Pediatric Rheumatology
Laura Aisenberg¹, Irit Rasooly¹, Pamela Weiss², Jon Burnham³ and Anna Costello¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Children's Hospital of Philadelphia, Bryn Mawr, PA
Background/Purpose: In early 2020, much of the country’s pediatric rheumatology practice shifted to a telehealth model secondary to the SARS-CoV-2 pandemic. During this discrete period,…
Abstract Number: 2201 • ACR Convergence 2024
Immunodeficiency-Related Monogenic Autoinflammatory Diseases; Expanding Spectrum of Immunodysregulation Disorders
Alhanouf Alsaleem¹, Lujain Akbar² and Sulaiman Al-Mayouf³, ¹KFSH&RC, Riyadh, Saudi Arabia, ²RIYADH, RIYADH, Saudi Arabia, ³KFSHRRC, Riyadh, Saudi Arabia
Background/Purpose: Human inborn errors of immunity are caused by monogenic germline mutations characterized by Immunodeficiency like features with increase susceptibility to infection as well as…
Abstract Number: 2573 • ACR Convergence 2024
Efficacy and Safety of Ixekizumab in Children with Active Juvenile Psoriatic Arthritis and Enthesitis Related Arthritis (COSPIRIT-JIA): 16-week Results of a Multicentre, Randomised, Open-label Study
Athimalaipet Ramanan¹, Nicolino Ruperto², Ivan Foeldvari³, Gabriel Vega Cornejo⁴, Stuart Keller⁵, Rona Wang⁵, Joana Araújo⁵, Maja Hojnik⁶, Priyanka Sen⁵, Ketan Marulkar⁵ and PIERRE QUARTIER⁷, ¹Bristol Royal Hosp for Children, Bristol, United Kingdom, ²IRCCS Giannina Gaslini, Genova, Italy, ³Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ⁴CREA de Guadalajara SC., Guadalajara, Mexico, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Eli Lilly and Co., Indianapolis, IN, ⁷Université Paris-Cite, IMAGINE Institute, Necker Children’s Hospital, Paris Cedex 15, France
Background/Purpose: Juvenile psoriatic arthritis (JPsA) and enthesitis-related-arthritis (ERA) are 2 categories of Juvenile Idiopathic Arthritis (JIA) according to the International League of Associations for Rheumatology…
Abstract Number: 0391 • ACR Convergence 2024
Using Machine Learning to Predict Inactive Disease in Juvenile Idiopathic Arthritis
Mei-Sing Ong¹, Marc Natter², Laura Schanberg³ and Yukiko Kimura⁴, and CARRA Registry Investigators, ¹Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, MA, ²Boston Children's Hospital, Boston, MA, ³Duke University Medical Center, DURHAM, NC, ⁴Hackensack Meridian School of Medicine, New York, NY
Background/Purpose: Optimizing treatment of JIA continues to be a challenge. Biologic DMARD (bDMARD) therapies have significantly improved outcomes but is costly, may be more difficult…
Abstract Number: 0637 • ACR Convergence 2024
Active Implementation of Low Disease Activity State as Treatment Endpoint in a Large Cohort of Adolescents and Young Adults with Childhood Onset Systemic Lupus Erythematosus
Ruby Gotch¹, Yumna Ahmed¹, Robert Wilson¹, Ellie Hawkins¹ and Coziana Ciurtin², ¹University College London Hospital NHS Trust, London, United Kingdom, ²University College London, London, United Kingdom
Background/Purpose: Treat-to-target (T2T) strategies are focused on proactive and tailored management of disease activity to minimise damage risk and improve long-term outcomes in SLE across…
Abstract Number: 1260 • ACR Convergence 2024
Toward a Treat-to-target Strategy in Juvenile Dermatomyositis: Seeking for Suitable Targets and Optimal Timing of Their Achievement
Silvia Rosina¹, Ana Isabel Rebollo-Giménez², Chiara Campone³, Valentina Natoli², Alessandro Consolaro², Francesca Bovis³ and Angelo Ravelli⁴, ¹IRCCS Istituto Giannina Gaslini, Genoa, Italy, ²IRCCS Istituto Giannina Gaslini, Genova, Italy, ³Università degli Studi di Genova, Genova, Italy, ⁴IRCCS Giannina Gaslini, Genoa, Italy
Background/Purpose: The management of juvenile dermatomyositis (JDM) is not standardized and no widely embraced therapeutic protocols are available. Furthermore, the optimal therapeutic targets as well…
Abstract Number: 1277 • ACR Convergence 2024
Why Did You Choose That Score? – Associations Between Patient Global Assessment Scores and Mental Health in Patients with Juvenile Idiopathic Arthritis and Systemic Lupus Erythematosus
Inna Powers¹, Sonja Ziniel², Jeanelle Sheeder³, Jessica Bloom⁴ and Brian Pitts¹, ¹University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, CO, ²University of Colorado School of Medicine, Aurora, CO, ³University of Colorado School of Medicine, Department of Obstetrics and Gynecology, Aurora, CO, ⁴University of Colorado, Denver, CO
Background/Purpose: Rheumatic disease in childhood significantly alters a child’s quality of life. The patient global assessment (PGA) score is a clinical and research tool that…
Abstract Number: 1763 • ACR Convergence 2024
Circulating NK and CD8+ Cytotoxic T Cells in Treatment Naïve JDM Demonstrate Higher Cytotoxic and Interferon Signature as Compared to Childhood-Onset SLE
Qinmengge Li¹, Celine Berthier¹, Christine Goudsmit¹, Sophia Matossian¹, Rachael Wasikowski², Johann Gudjonsson¹, J. Michelle Kahlenberg¹, Lam C. Tsoi² and Jessica Turnier³, ¹University of Michigan, Ann Arbor, MI, ²Michigan, Dept. of Dermatology, Ann Arbor, MI, ³University of Michigan, Saline, MI
Background/Purpose: Juvenile dermatomyositis (JDM) and childhood-onset systemic lupus erythematosus (cSLE) are pediatric autoimmune diseases that can present with overlapping clinical features yet have unique tropism…
Abstract Number: 1803 • ACR Convergence 2024
Genetics of eGFR Variability as a Proxy for Lupus Nephritis in Patients with Systemic Lupus Erythematosus
Magdalena Riedl Khursigara¹, Nicholas Gold², Thai-Son Tang³, JingJing Cao⁴, Daniela Dominguez⁴, Marisa Klein-Gitelman⁵, Dafna Gladman⁶, Daniel Goldman⁷, Elizabeth Harvey⁴, Mariko Ishimori⁸, Caroline Jefferies⁹, Diane Kamen¹⁰, Sylvia Kamphuis¹¹, Andrea Knight¹², Chia-Chi Lee¹³, Deborah Levy², Damien Noone⁴, Karen Onel¹⁴, Christine Peschken¹⁵, Michelle Petri⁷, Janet Pope¹⁶, Eleanor Pullenayegum⁴, Earl Silverman¹⁷, Zahi Touma¹⁸, Murray Urowitz¹⁹, Daniel Wallace²⁰, Joan Wither²¹ and Linda Hiraki², and Systemic Lupus Erythematosus Collaborative Clinics (SLICC), ¹University of Toronto, Cambridge, MA, ²The Hospital for Sick Children, Toronto, ON, Canada, ³University of Toronto, Mississauga, ON, Canada, ⁴The Hospital for Sick Children, Toronto, Canada, ⁵Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁶University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁷Johns Hopkins University School of Medicine, Timonium, MD, ⁸Cedars-Sinai Health System, Los Angeles, CA, ⁹Cedars-Sinai Medical Center, Beverly Hills, CA, ¹⁰Medical University of South Carolina, Charleston, SC, ¹¹Erasmus University Medical Center, Rotterdam, Netherlands, ¹²Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ¹³Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁴HSS, New York, NY, ¹⁵University of Manitoba, Winnipeg, MB, Canada, ¹⁶University of Western Ontario, London, ON, Canada, ¹⁷Silverman, Toronto, ON, Canada, ¹⁸University of Toronto, Toronto, ON, Canada, ¹⁹Self employed, Toronto, ON, Canada, ²⁰Cedars Sinai Medical Center, Studio City, CA, ²¹University Health Network, Toronto, ON, Canada
Background/Purpose: Lupus nephritis (LN) is one of the most common and severe manifestations of systemic lupus erythematosus (SLE). We performed genome wide association studies (GWAS)…
Abstract Number: 2180 • ACR Convergence 2024
The Association Between Age at Diagnosis and Patient-Reported Outcomes in Patients with Vasculitis
Jessica Bloom¹, Kaci Pickett-Nairne², Lori Silveira², David Cuthbertson³, Carol McAlear⁴, Peter Merkel⁴ and Karen James⁵, and the Vasculitis Clinical Research Consortium, ¹University of Colorado, Denver, CO, ²University of Colorado, Aurora, CO, ³University of South Florida, Tampa, FL, ⁴University of Pennsylvania, Philadelphia, PA, ⁵University of Utah, Salt Lake City, UT
Background/Purpose: Vasculitis is a chronic autoimmune condition that significantly impacts patients’ quality of life. It is unknown whether the degree of this impact varies based…

« Previous Page
1
…
5
6
7
8
9
…
52
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].